Lexaria Bioscience Corp.
General ticker "LEXX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $19.4M (TTM average)
Lexaria Bioscience Corp. does not follow the US Stock Market performance with the rate: -29.4%.
Estimated limits based on current volatility of 7.8%: low 10.93$, high 12.77$
Factors to consider:
- Total employees count: 7 (+40.0%) as of 2024
- Top business risk factors: Substantial doubt about continuing as a going concern, Inability to secure additional financing, Commercialization failure, Labor/talent shortage/retention, Market competition
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-08-31 to 2027-08-31
- 2025-08-31 to 2026-08-31 estimated range: [5.20$, 18.88$]
- 2026-08-31 to 2027-08-31 estimated range: [3.24$, 12.17$]
Financial Metrics affecting the LEXX estimates:
- Negative: with PPE of -1.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -66.47 <= 0.28
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 71.61 > 63.63
- Negative: negative Industry operating cash flow (median)
- Negative: -0.14 < Industry inventory ratio change (median), % of 0
Short-term LEXX quotes
Long-term LEXX plot with estimates
Financial data
| YTD | 2023-08-31 | 2024-08-31 | 2025-08-31 |
|---|---|---|---|
| Operating Revenue | $0.23MM | $0.46MM | $0.71MM |
| Operating Expenses | $6.76MM | $6.22MM | $12.59MM |
| Operating Income | $-6.53MM | $-5.75MM | $-11.88MM |
| Non-Operating Income | $-0.22MM | $-0.06MM | $-0.06MM |
| R&D Expense | $3.67MM | $2.36MM | $8.24MM |
| Income(Loss) | $-6.76MM | $-5.81MM | $-11.94MM |
| Net Income(Loss)* | $-6.66MM | $-5.80MM | $-11.90MM |
| Stockholders Equity | $3.04MM | $8.04MM | $2.99MM |
| Assets | $3.08MM | $8.87MM | $4.18MM |
| Operating Cash Flow | $-5.88MM | $-4.96MM | $-10.45MM |
| Capital expenditure | $0.17MM | $0.04MM | $0.02MM |
| Investing Cash Flow | $-0.17MM | $-0.19MM | $-0.24MM |
| Financing Cash Flow | $1.59MM | $10.32MM | $6.05MM |
| Earnings Per Share** | $-15.12 | $-7.02 | $-9.92 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.